Blood Res.  2023 Jun;58(2):112-115. 10.5045/br.2023.2022241.

End of induction MRD assessment based early treatment intensification with novel agents in ETP-ALL- may be the way forward

• Patra PC
• Rainchwar S
• Singh R
• Halder R
• Mehta P
• Verma M
• Ahmed R
• Raichaudhuri JS
• Bhurani D
• Agrawal N
• Pramanik S

• KMID: 2543952
• DOI: http://doi.org/10.5045/br.2023.2022241

Figure

• 

  Fig. 1 Consort flow diagram of patients and their outcomes.

• 

  Fig. 2 Survival of the entire study population (N=11). (A) Median overall survival (OS) survival time: not reached (95% LCL, 27; 95% UCL, not reached). (B) Median progression free survival (PFS) survival time: not reached (95% LCL, 27; 95% UCL, not reached).

Reference

1. Borowitz MJ, Chan JKC, Downing JR, Le Beau MM, Arber DA. 2017; Precursor lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France:. IARC. 199–213. DOI: 10.53347/rid-9250.

2. Jain N, Lamb AV, O'Brien S, et al. 2016; Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 127:1863–9. DOI: 10.1182/blood-2015-08-661702. PMID: 26747249. PMCID: PMC4915808.

3. Zhang Y, Qian JJ, Zhou YL, et al. 2020; Comparison of early T-cell precursor and non-ETP subtypes among 122 Chinese adults with acute lymphoblastic leukemia. Front Oncol. 10:1423. DOI: 10.3389/fonc.2020.01423. PMID: 32974153. PMCID: PMC7473208. PMID: 04fa1d45900b4e4a84fe67e26e49d3d1.

4. Mirgh S, Ahmed R, Agrawal N, et al. 2019; Will daratumumab be the next game changer in early thymic precursor-acute lymphoblastic leukaemia? Br J Haematol. 187:e33–5. DOI: 10.1111/bjh.16154. PMID: 31452197.

5. Bond J, Graux C, Lhermitte L, et al. 2017; Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a group for research on adult acute lymphoblastic leukemia study. J Clin Oncol. 35:2683–91. DOI: 10.1200/JCO.2016.71.8585. PMID: 28605290.

6. Wood BL, Winter SS, Dunsmore KP, et al. 2014; T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children's Oncology Group (COG) Study AALL0434. Blood (ASH Annual Meeting Abstracts). 124(Suppl):1. DOI: 10.1182/blood.V124.21.1.1.